Haemonetics (NYSE:HAE) had its target price upped by equities researchers at Jefferies Group from $18.00 to $75.00 in a note issued to investors on Monday, The Fly reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. Jefferies Group’s price objective points to a potential upside of 18.32% from the company’s previous close. Jefferies Group also issued estimates for Haemonetics’ Q3 2018 earnings at $0.45 EPS, Q4 2018 earnings at $0.40 EPS, FY2018 earnings at $1.66 EPS, FY2019 earnings at $2.00 EPS, FY2020 earnings at $2.80 EPS, FY2021 earnings at $3.75 EPS and FY2022 earnings at $4.35 EPS.
A number of other brokerages have also issued reports on HAE. Raymond James Financial upgraded Haemonetics from an “underperform” rating to a “market perform” rating in a research report on Tuesday, January 2nd. Morgan Stanley upgraded Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price target for the company in a research report on Tuesday, January 2nd. Zacks Investment Research lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, November 20th. Craig Hallum reiterated a “hold” rating and set a $50.00 price target (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. Finally, Barrington Research boosted their price target on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Haemonetics has an average rating of “Hold” and an average price target of $58.83.
Haemonetics (NYSE:HAE) traded up $0.76 during trading hours on Monday, reaching $63.39. The company had a trading volume of 426,800 shares, compared to its average volume of 577,950. Haemonetics has a twelve month low of $36.44 and a twelve month high of $63.90. The firm has a market cap of $3,350.00, a price-to-earnings ratio of 905.57, a P/E/G ratio of 4.71 and a beta of 0.99. The company has a quick ratio of 1.51, a current ratio of 2.17 and a debt-to-equity ratio of 0.22.
In other news, Director Ronald G. Gelbman sold 5,440 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $56.69, for a total value of $308,393.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Dan Goldstein sold 4,691 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $54.93, for a total value of $257,676.63. Following the completion of the sale, the chief accounting officer now owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The disclosure for this sale can be found here. In the last 90 days, insiders sold 54,486 shares of company stock valued at $3,050,827. Insiders own 1.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in HAE. Victory Capital Management Inc. lifted its holdings in shares of Haemonetics by 18.7% in the third quarter. Victory Capital Management Inc. now owns 2,414,526 shares of the medical instruments supplier’s stock valued at $108,340,000 after buying an additional 381,012 shares during the period. HealthCor Management L.P. lifted its holdings in shares of Haemonetics by 15.9% in the second quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock valued at $73,249,000 after buying an additional 254,872 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Haemonetics by 9.3% in the second quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock valued at $110,104,000 after buying an additional 238,294 shares during the period. Neuberger Berman Group LLC lifted its holdings in shares of Haemonetics by 10.2% in the third quarter. Neuberger Berman Group LLC now owns 2,053,458 shares of the medical instruments supplier’s stock valued at $92,139,000 after buying an additional 189,797 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Haemonetics in the second quarter valued at $6,115,000.
ILLEGAL ACTIVITY WARNING: “Haemonetics (HAE) Price Target Raised to $75.00 at Jefferies Group” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2018/01/10/haemonetics-hae-price-target-raised-to-75-00-at-jefferies-group.html.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.